Original ArticleNicotinamide mononucleotide alleviates angiotensin II-induced human aortic smooth muscle cell senescence in a microphysiological modelYin, Xiujie MD1,#; Abudupataer, Mieradilijiang MD1,#; Ming, Yang MD1,#; Xiang, Bitao MD1; Lai, Hao MD1; Wang, Chunsheng MD1,*; Li, Jun MD1,*; Zhu, Kai MD1,* Author Information 1Department of Cardiac Surgery and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai 20032, China. *Correspondence to: Kai Zhu at [email protected]; Jun Li at [email protected]; Chunsheng Wang at [email protected]. The authors have no conflicts of interest to declare. #Xiujie Yin, Mieradilijiang Abudupataer, and Yang Ming contributed equally to this work. Journal of Cardiovascular Pharmacology ():10.1097/FJC.0000000000001400, January 18, 2023. | DOI: 10.1097/FJC.0000000000001400 Buy PAP Metrics Abstract The occurrence and development of aortic aneurysms are accompanied by senescence of human aortic smooth muscle cells (HASMCs). As the mechanism of HASMC senescence has not been fully elucidated, the efficacy of various anti-senescence treatments varies. Decreased nicotinamide adenine dinucleotide (NAD+) levels are one of the mechanisms of cell senescence, and there is a lack of evidence on whether increasing NAD+ levels could alleviate HASMC senescence and further retard the progression of aortic aneurysms. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
